cisplatin • carboplatin • 5-fluorouracil • doxorubicin hydrochloride • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • Jemperli (dostarlimab-gxly)

NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)

P2, N=51, Suspended, Gustave Roussy, Cancer Campus, Grand Paris | N=112 --> 51 | Trial completion date: Mar 2027 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Dec 2024

1 month ago

Enrollment change • Trial completion date • Trial suspension • Trial primary completion date • Pan tumor

HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)

HER-2 positive • HER-2 amplification • DDR • PBRM1 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

If it's a target, it's a pan-cancer target: Tissue is not the issue. (PubMed, Cancer Treat Rev)

Hence, we now have multiple genomic biomarker-based, tissue-agnostic Food and Drug Administration approvals for both gene- and immune-targeted therapies (larotrectinib/entrectinib, for NTRK fusions; selpercatinib, RET fusions; dabrafenib plus trametinib, BRAFV600E mutations; pembrolizumab/dostarlimab, microsatellite instability; and pembrolizumab for high tumor mutational burden; pemigatinib is also approved for FGFR1-rearranged myeloid/lymphoid neoplasms). Resistance to biomarker-driven therapeutics is often due to secondary mutations or co-driver gene defects; studies are now addressing the need for customized drug combinations matched to the complex molecular alteration portfolio in each tumor. Future investigation should expand tissue-agnostic therapeutics to encompass both hematologic and solid malignancies and include biomarkers beyond those that are DNA-based.

1 month ago

Review • Journal • Tumor mutational burden • BRCA Biomarker • PD(L)-1 Biomarker • Pan tumor

HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • FGFR1 (Fibroblast growth factor receptor 1) • NRG1 (Neuregulin 1) • BRCA (Breast cancer early onset) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • TMB-H • KRAS G12C • BRAF V600 • RET fusion • KRAS G12 • NTRK fusion

Keytruda (pembrolizumab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Retevmo (selpercatinib) • Jemperli (dostarlimab-gxly) • Pemazyre (pemigatinib)

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)

P1, N=475, Recruiting, GlaxoSmithKline

1 month ago

New P1 trial • Metastases

Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)

RUBY-J: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov)

P2, N=36, Not yet recruiting, GlaxoSmithKline

1 month ago

New P2 trial • Combination therapy • Metastases

carboplatin • paclitaxel • Jemperli (dostarlimab-gxly)

2ms

TOPAZ: A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers (clinicaltrials.gov)

P1/2, N=38, Recruiting, Joseph Caster, Ph.D., M.D. | Phase classification: P1b/2 --> P1/2

2 months ago

Phase classification • Metastases

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

2ms

Dostarlimab and Cobolimab in Advanced Cervical Cancer (clinicaltrials.gov)

P2, N=66, Recruiting, Meghan Shea | Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Mar 2024

2 months ago

Enrollment open • Trial initiation date • Combination therapy • Metastases

Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)

2ms

Cost effectiveness of immunotherapy combination therapies for endometrial cancer. (PubMed, Gynecol Oncol Rep)

As such, we reviewed FDA approvals from 2019 to 2013 and identified the following approvals in gynecologic oncology: pembrolizumab plus lenvatinib, pembrolizumab for recurrent endometrial cancer that is MSI-H/dMMR, tisotumab vedotin, dostarlimab as single-agent therapy, and dostarlimab plus chemotherapy. We focused on approvals for endometrial cancer, and conducted a cost-effectiveness analysis for combination options approved in treating recurrent or advanced endometrial cancer (i.e. pembrolizumab plus lenvatinib versus placebo; dostarlimab plus chemotherapy versus placebo), and found neither regimen was cost-effective at a willingness-to-pay of $100,000 per Equal Value of Life Years Gained (evLYG). While these costs may not necessarily be translated to an individual patient, these costs are absorbed by healthcare systems and insurance providers on a larger scale with downstream effects on individuals contributing to healthcare costs a whole.

2 months ago

Journal • HEOR • Combination therapy • Cost-effectiveness • Cost effectiveness

MSI (Microsatellite instability)

MSI-H/dMMR

Keytruda (pembrolizumab) • Lenvima (lenvatinib) • Jemperli (dostarlimab-gxly) • Tivdak (tisotumab vedotin-tftv)

2ms

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 (clinicaltrials.gov)

P1/2, N=21, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026

2 months ago

Trial completion date • Trial primary completion date

CD4 (CD4 Molecule)

Jemperli (dostarlimab-gxly) • LB-100

2ms

IMPRESS-Norway: Improving Public Cancer Care by Implementing Precision Medicine in Norway (clinicaltrials.gov)

P2, N=3000, Recruiting, Oslo University Hospital | N=1000 --> 3000

2 months ago

Enrollment change

Avastin (bevacizumab) • Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Perjeta (pertuzumab) • Zejula (niraparib) • Zykadia (ceritinib) • Jemperli (dostarlimab-gxly) • Erivedge (vismodegib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)

2ms

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) (clinicaltrials.gov)

P2, N=10, Not yet recruiting, Queensland Centre for Gynaecological Cancer

2 months ago

New P2 trial

Jemperli (dostarlimab-gxly)

2ms

DORA: DOstarlimab in Patients With Recurrent or dMMR/MSI-H Endometrial Cancer (clinicaltrials.gov)

P=N/A, N=100, Recruiting, Grupo Español de Investigación en Cáncer de Ovario | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Aug 2023 --> Apr 2024

2 months ago

Trial completion date • Trial primary completion date • Real-world evidence • Mismatch repair • Real-world • Metastases

MSI (Microsatellite instability)

MSI-H/dMMR

Jemperli (dostarlimab-gxly)

2ms

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer (clinicaltrials.gov)

P2, N=66, Recruiting, University of Oklahoma

2 months ago

Trial completion date • Trial primary completion date • Combination therapy

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

2ms

ACCeSs: Study on TSR-042 in Advanced Clear Cell Sarcoma (clinicaltrials.gov)

P2, N=3, Terminated, Italian Sarcoma Group | N=16 --> 3 | Trial completion date: May 2024 --> Jan 2024 | Active, not recruiting --> Terminated | Trial primary completion date: May 2024 --> Jan 2024; Difficulty of enrollment

2 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1)

Jemperli (dostarlimab-gxly)

2ms

JADE: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)

P3, N=864, Not yet recruiting, GlaxoSmithKline

2 months ago

New P3 trial • Metastases

Jemperli (dostarlimab-gxly)

2ms

Dostarlimab and Cobolimab in Advanced Cervical Cancer (clinicaltrials.gov)

P2, N=66, Not yet recruiting, Meghan Shea

2 months ago

New P2 trial • Combination therapy • Metastases

Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)

3ms

DEWI: Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (clinicaltrials.gov)

P2, N=59, Recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)

MSI-H/dMMR

Jemperli (dostarlimab-gxly)

3ms

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)

P2, N=360, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Trial completion date: Mar 2027 --> Aug 2027 | Trial primary completion date: Mar 2027 --> Sep 2025

3 months ago

Enrollment open • Trial completion date • Trial primary completion date • Metastases

PD-L1 (Programmed death ligand 1)

PD-L1 expression

Jemperli (dostarlimab-gxly) • GSK6097608

3ms

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer (clinicaltrials.gov)

P2, N=22, Active, not recruiting, Mayo Clinic | Trial primary completion date: Sep 2024 --> Dec 2023

3 months ago

Trial primary completion date • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1)

PD-L1 expression • PD-1 expression

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

4ms

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) (clinicaltrials.gov)

P2, N=198, Not yet recruiting, Yonsei University | Initiation date: Sep 2023 --> Jan 2024

4 months ago

Trial initiation date

MSI (Microsatellite instability) • PD-1 (Programmed cell death 1) • WT1 (WT1 Transcription Factor)

Avastin (bevacizumab) • gemcitabine • paclitaxel • Jemperli (dostarlimab-gxly) • pegylated liposomal doxorubicin

4ms

DEWI: Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study (clinicaltrials.gov)

P2, N=59, Not yet recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group | Initiation date: Sep 2023 --> Jan 2024

4 months ago

Trial initiation date • Mismatch repair

MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)

MSI-H/dMMR

Jemperli (dostarlimab-gxly)

4ms

TIG-006: Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1/2, N=254, Recruiting, iTeos Belgium SA | N=376 --> 254 | Trial completion date: Sep 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Sep 2024

4 months ago

Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Pan tumor • Metastases

Keytruda (pembrolizumab) • Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • inupadenant (EOS-850)

4ms

DIDO: Niraparib and Dostarlimab in HRD Solid Tumors (clinicaltrials.gov)

P2, N=30, Recruiting, West Cancer Center | Not yet recruiting --> Recruiting

4 months ago

Enrollment open • Combination therapy • Metastases

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • RAD54L (DNA Repair And Recombination Protein RAD54) • FANCL (FA Complementation Group L) • PPP2R2A (Protein Phosphatase 2, Regulatory Subunit B, Alpha) • FANCI (FA Complementation Group I)

BRCA1 mutation • HRD • ATM mutation • PALB2 mutation • CHEK2 mutation • BRIP1 mutation • HRD + BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • FANCI mutation • RAD51 mutation

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

4ms

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial. (PubMed, Clin Cancer Res)

This preliminary analysis highlighted the lack of antitumor activity for the combination of niraparib and dostarlimab in patients with PM and/or advanced NSCLC harboring BAP1 somatic mutations. A potential antitumor activity emerged for PM with germline BAP1 and/or BRCA2 somatic mutations along with a good tolerability profile.

4 months ago

P2 data • Journal • BRCA Biomarker • PARP Biomarker • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BAP1 (BRCA1 Associated Protein 1)

BRCA2 mutation • BAP1 mutation

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

5ms

RADIAN: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)

P1/2, N=34, Recruiting, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

5 months ago

Trial completion date • Trial primary completion date • Metastases

cisplatin • Zejula (niraparib) • Jemperli (dostarlimab-gxly)

5ms

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (clinicaltrials.gov)

P1, N=58, Active, not recruiting, Tesaro, Inc. | Phase classification: P1b --> P1

5 months ago

Phase classification

Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Zejula (niraparib) • albumin-bound paclitaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)

5ms

ACCeSs: Study on TSR-042 in Advanced Clear Cell Sarcoma (clinicaltrials.gov)

P2, N=16, Active, not recruiting, Italian Sarcoma Group | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1)

Jemperli (dostarlimab-gxly)

5ms

AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer. (ASCO-GI 2024)

Editorial support provided by Fishawack Health, funded by GSK. Clinical trial information: NCT05855200.

5 months ago

Clinical • P3 data

MSI (Microsatellite instability)

MSI-H/dMMR

5-fluorouracil • Jemperli (dostarlimab-gxly) • leucovorin calcium

5ms

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery (clinicaltrials.gov)

P2, N=31, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting

5 months ago

Enrollment closed • Checkpoint inhibition • Mismatch repair • Surgery • Checkpoint block • Metastases

MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)

MSI-H/dMMR • POLE mutation

Jemperli (dostarlimab-gxly)

5ms

Phase 1 First Time in Human (FTIH), Open Label Study of GSK3745417 Administered to Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=98, Active, not recruiting, GlaxoSmithKline | Trial completion date: Aug 2024 --> Apr 2024

5 months ago

Trial completion date • Metastases

Jemperli (dostarlimab-gxly) • GSK3745417

5ms

Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). (PubMed, Gynecol Oncol)

The study was terminated due to the observed ORR at the interim futility analysis. This highlights a need for effective therapies in treating patients with recurrent BRCAwt PROC.

5 months ago

Clinical • P2 data • Journal

BRCA (Breast cancer early onset)

BRCA wild-type

Avastin (bevacizumab) • Zejula (niraparib) • Jemperli (dostarlimab-gxly)

5ms

Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer. (PubMed, Sci Rep)

Immunotherapy, while not yet a mainstream treatment for gynecologic cancers, is advancing, with Dostarlimab recently receiving approval as a treatment for endometrial cancer...To explore the relationship between distant tissue biopsy regions and blood circulation, we investigated the TCR beta chain (TCRβ) in bulk tumor and matched blood samples from 39 patients with gynecologic cancer. We found that the TCR clones of TILs at different tumor sites were globally shared within patients and had high overlap with the TCR clones in peripheral blood.

5 months ago

Journal • Tumor-infiltrating lymphocyte • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker • Metastases

PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • TRB (T Cell Receptor Beta Locus)

BRCA1 expression • BRCA2 expression

Jemperli (dostarlimab-gxly)

5ms

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 (clinicaltrials.gov)

P1/2, N=21, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Mar 2024 --> Nov 2023

5 months ago

Enrollment open • Trial initiation date

CD4 (CD4 Molecule)

Jemperli (dostarlimab-gxly) • LB-100

5ms

RADIAN: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)

P1/2, N=34, Recruiting, Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | Not yet recruiting --> Recruiting

5 months ago

Enrollment open • Metastases

cisplatin • Zejula (niraparib) • Jemperli (dostarlimab-gxly)

6ms

NADiR: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (clinicaltrials.gov)

P2; Trial primary completion date: Apr 2023 --> Apr 2025

6 months ago

Trial primary completion date • Metastases

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)

HER-2 amplification • HER-2 negative • PD-L1 negative

PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay

Zejula (niraparib) • Jemperli (dostarlimab-gxly)

6ms

Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England. (PubMed, Int J Gynecol Cancer)

In this adjusted indirect dataset, patients with recurrent/advanced mismatch repair deficient/microsatellite instability-high endometrial cancer post-platinum-based chemotherapy who received dostarlimab in the GARNET trial had significantly improved overall survival compared with patients receiving current second-line treatment in England.

6 months ago

Journal • Metastases

MSI (Microsatellite instability)

MSI-H/dMMR

Jemperli (dostarlimab-gxly)

6ms

DREAMM 5: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)

P1/2, N=464, Recruiting, GlaxoSmithKline | Trial completion date: Feb 2028 --> Feb 2029 | Trial primary completion date: Feb 2025 --> Feb 2026

6 months ago

Trial completion date • Trial primary completion date • Combination therapy

lenalidomide • Jemperli (dostarlimab-gxly) • dexamethasone • pomalidomide • Sarclisa (isatuximab-irfc) • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat) • feladilimab (GSK3359609) • GSK3174998

6ms

COSTAR Lung: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-Small Cell Lung Cancer Who Have Progressed on Prior Anti- Programmed Death-ligand 1 (PD-[L]1) Therapy and Chemotherapy (clinicaltrials.gov)

P2/3, N=758, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting

6 months ago

Enrollment closed • Metastases • Cost of therapy

docetaxel • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)

6ms

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery (clinicaltrials.gov)

P2, N=31, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

6 months ago

Trial completion date • Trial primary completion date • Checkpoint inhibition • Mismatch repair • Surgery • Checkpoint block • Metastases

MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)

MSI-H/dMMR • POLE mutation

Jemperli (dostarlimab-gxly)